Holen Sie sich die Stockscreener-App
2.695
0.16%
0.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt AVXL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.695
Offen:
$2.69
24-Stunden-Volumen:
467.51K
Relative Volume:
0.35
Marktkapitalisierung:
$249.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.95M
KGV:
-5.7969
EPS:
-0.4649
Netto-Cashflow:
$-34.08M
1W Leistung:
+1.10%
1M Leistung:
-19.18%
6M Leistung:
-30.07%
1J Leistung:
-64.15%
1-Tages-Spanne:
$2.69
$2.80
1-Wochen-Bereich:
$2.635
$2.80
52-Wochen-Spanne:
$2.61
$13.99
Anavex Life Sciences Corp Stock (AVXL) Company Profile
Firmenname
Anavex Life Sciences Corp
Sektor
Branche
Telefon
844-689-3939
Adresse
630 5TH AVENUE, NEW YORK
Compare AVXL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corp
|
2.695 | 249.75M | 0 | -39.95M | -34.08M | -0.4649 |
VRTX
Vertex Pharmaceuticals Inc
|
437.23 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.14 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.38 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.77 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.17 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anavex Life Sciences Corp Stock (AVXL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | Eingeleitet | Berenberg | Buy |
| 2021-09-23 | Eingeleitet | BTIG Research | Buy |
| 2020-12-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-28 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-02-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-18 | Eingeleitet | Janney | Buy |
| 2018-05-16 | Fortgesetzt | Maxim Group | Buy |
| 2018-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-13 | Bestätigt | Maxim Group | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-02-07 | Eingeleitet | Noble Financial | Buy |
| 2016-03-29 | Eingeleitet | FBR Capital | Outperform |
Alle ansehen
Anavex Life Sciences Corp Aktie (AVXL) Neueste Nachrichten
Anavex Life Sciences (AVXL) Faces Nasdaq Compliance Challenge - GuruFocus
Anavex (AVXL) Faces Nasdaq Notification Due to Filing Delay - GuruFocus
Anavex Life Sciences receives Nasdaq delisting warning - Investing.com UK
Anavex Life Sciences receives Nasdaq delisting warning By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
Anavex Life Sciences receives expected Nasdaq delinquency notification - marketscreener.com
Anavex Life Sciences Received Notice of Noncompliance - TradingView
Nasdaq warns Anavex (Nasdaq: AVXL) over delayed quarterly filing - Stock Titan
Anavex Life Sciences Corp. Receives Delinquency Notification from Nasdaq for Non-Compliance with Listing Rule - Quiver Quantitative
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification - Anavex Life Sciences
Nasdaq flags Anavex for missing 10-Q, gives July 20 fix date - Stock Titan
AVXL Stock Price, Quote & Chart | ANAVEX LIFE SCIENCES CORP (NASDAQ:AVXL) - ChartMill
Anavex Life Sciences stock crushed as European Alzheimer's drug filing pulled after EMA pushback - MSN
Anavex Life Sciences Announces COO Departure Amid Restructuring - The Globe and Mail
Anavex (AVXL) COO exits amid reorganization; option grant largely forfeited - Stock Titan
Anavex (AVXL) interim CEO discloses detailed stock option grants - Stock Titan
Anavex withdraws EU approval filing for Alzheimer’s therapy - MSN
Anavex Stock Just Logged Its Worst Selloff In 2 Years — What Does EMA’s Oral Explanation Week Mean For Its Alzheimer’s Drug? - MSN
AVXL stock tanks after Anavex withdraws EU bid for Alzheimer's drug - MSN
Anavex Delays Quarterly Filing Amid CEO Shake-Up - The Globe and Mail
TradingKey - TradingKey
Anavex Life Sciences (AVXL) Delays Quarterly Report Submission - GuruFocus
AVXL SEC FilingsAnavex Life Scie 10-K, 10-Q, 8-K Forms - Stock Titan
Anavex Life Sciences (NASDAQ: AVXL) delays 10-Q after CEO termination - Stock Titan
MSN Money - MSN
Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring A 605% Upside Potential - DirectorsTalk Interviews
Biopharma veteran takes her CEO Cue—Chutes & Ladders - Fierce Biotech
Anavex (AVXL) Appoints Interim CEO Amid Leadership Change - GuruFocus
Anavex Life Sciences Names Interim CEO Amid Leadership Shift - The Globe and Mail
Number of shareholders of Anavex Life Sciences Corp. – FWB:12X1 - TradingView
Anavex Life Sciences Appoints Terrie Kellmeyer as Interim CEO Following Christopher Missling’s Departure - Minichart
Anavex appoints interim CEO following leadership change - Investing.com UK
CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus - Yahoo Finance
Anavex stock slips after CEO transition (AVXL:NASDAQ) - Seeking Alpha
Anavex appoints interim CEO following leadership change By Investing.com - Investing.com India
CEO ousted as Anavex (NASDAQ: AVXL) board installs interim chief and eyes 10-Q delay - Stock Titan
Anavex Life Sciences (AVXL) to Release Earnings on Tuesday - MarketBeat
H.C. Wainwright initiates Anavex Life Sciences stock with buy rating - Investing.com UK
H.C. Wainwright initiates Anavex Life Sciences stock with buy rating By Investing.com - Investing.com South Africa
Director Axel Paeger files initial Form 3 for Anavex (AVXL) - Stock Titan
Finanzdaten der Anavex Life Sciences Corp-Aktie (AVXL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Anavex Life Sciences Corp-Aktie (AVXL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thomas Steffen | Director |
Jun 05 '25 |
Option Exercise |
1.76 |
50,000 |
88,000 |
55,000 |
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):